Management
Christian Schaub, co-founder, CEO and President
Engineer (masters degree ETH Zurich), successful entrepreneur setting-up hightech business. Business and technology consultant for finance institutes and industrial companies for more than 18 years. De Vigier Prize Winner 2007. Lecturer at ETH Zurich for strategy and marketing.
Dr. Corinne John, co-founder, Executive Vice President
Corinne John is co-founder and board member of Redbiotec AG. She obtained her PhD in the field of biochemistry from the ETH Zürich and performed research at Harvard Medical School in Boston, USA. She has more than 10 years of research experience in the field of protein co-expression. Corinne received several entrepreneurship prizes including the W.A. de Vigier Award 2007. Corinne holds a M.Sc. in Biotechnology of the École Supérieure de Biotechnologie de Strasbourg (ESBS) and a technology entrepreneurship degree from the executive school of the HSG.
Dr. Lilli Stergiou, CSO
Lilli joined Redbiotec in 2012 to advance Redbiotec’s science and business. Owner of a company herself and founding member of the non-profit organization LSZYSN, she was part of the team that led to Redbiotec’s CMV program acquisition by Pfizer end of 2014. She holds a degree in Chemistry and Biotechnology, a PhD in Molecular Biology and Genetics, with 5 years of postdoctoral experience and 7 years in the pharma/biotech industry. Since 2015 she is the head of the HSV2 vaccine program. In November 2017 Lilli was appointed CSO of the Company.
Dr. Marina Studart, Senior Scientist, Co-Leader Oncology program
Marina has a B.Sc. degree in Biology, a M.Sc. in Genetics and Evolution and a PhD from ETH Zurich in the field of Biochemistry. Her PhD study was a major contribution to the understanding of an alternative biochemical pathway for the synthesis of vitamin B6. She joined Redbiotec in 2013 to work with the team running the CMV program. After the acquisition of the CMV program by Pfizer, she took the leadership of Redbiotec’s project on the development of a vaccine against influenza together with six partners throughout Europe.
Board of Directors
Christian Schaub, Chairman of the board, CEO and co-founder
Engineer (masters degree ETH Zurich), successful entrepreneur setting-up hightech business. Business and technology consultant for finance institutes and industrial companies for more than 14 years. De Vigier Prize Winner 2007. Lecturer at ETH Zurich for strategy and marketing.
Dr. Michael Sidler, Member of the board, Partner/co-founder at Redalpine Venture Partners AG
Dr. Michael Sidler joined the Redbiotec Board in 2009. Michael is a founding member of Redalpine Venture Partners AG, Zurich and is General Partner for the Redalpine Capital I fund (Luxemburg). Before becoming an Investor, he was responsible for Corporate Investments and M&A at Prionics, a Biotech Startup based in Schlieren. From 1998 to 2003, Michael worked for The Boston Consulting Group in Zurich and Toronto in different functions as a project manager. Michael is in various organizations, juries, and advisory boards for the development and support of start-up companies such as CTI Startup, Venturekick, CTI Invest, SECA, Technopark Zürich und Glatec. In addition to his engagement in Zurich, he is a partner at Intro International AS, a Norwegian company commercializing emerging technologies. He studied biology at the University of Zurich and received his PhD in 1998.
Dr. Corinne John, Member of the board, co-founder
Corinne John is co-founder and board member of Redbiotec AG. She obtained her PhD in the field of biochemistry from the ETH Zürich and performed research at Harvard Medical School in Boston, USA. She has more than 10 years of research experience in the field of protein co-expression. Corinne received several entrepreneurship prizes including the W.A. de Vigier Award 2007.
Corinne holds a M.Sc. in Biotechnology of the École Supérieure de Biotechnologie de Strasbourg (ESBS) and a technology entrepreneurship degree from the executive school of the HSG.
Dr. med. Hans-Peter Richard, Member of the board, Private Investor
Dr. Hans-Peter Richard is a Medical Doctor specialized on premedical lifestyle management. As an active private investor, he partners up with a venture capital fund and is managing direct investments in start-ups and fast growing companies. He is focusing on sectors such as life science, science based consumer goods and luxury goods. He is member of the board at several other companies besides Redbiotec. At the University of Bern he is a visiting lecturer. He also served as a board member for Oettinger Davidoff group till 2005.